Quest Diagnostics
2nd Floor
Collegeville, PA 19426
Share:
Genetic Interpretive Service covers cystic fibrosis.
GenomEx(TM) provides personalized interpretation and reporting for complex genetic carrier testing. Platform-neutral service combines personal risk information with mutation/variant test results to generate personalized revised carrier risk assessment reports that are reviewed and released by board-certified clinical molecular geneticist. Information is transmitted via Focus LinkÃ-® secure...
Read More »Quest Diagnostics to Acquire U.S. Laboratory Services Business of Oxford Immunotec
Acquisition to broaden access to tuberculosis (TB) IGRA blood testing in the United States SECAUCUS, N.J. and OXFORD, England and MARLBOROUGH, Mass., Sept. 25, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced the...
Read More »Quest Diagnostics to Acquire Celera, Strengthening Position as World's Leading Innovator in Molecular Diagnostics and Development
Provides Immediate Access to Proprietary Genetic Tests and Pipeline of Biomarkers to Drive Sustainable Growth Berkeley HeartLab Brings Unique Esoteric Cardiovascular Test Offering and Specialized Sales Force Adds Leading Genetic IVD Products and Development Capability Transaction Valued at Approximately $344 Million, Net of Acquired Cash and Short-Term Investments MADISON, N.J. and ALAMEDA,...
Read More »Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market
Addition of Premier Provider of Neurology Testing to Complement Quest Diagnostics' Leadership in Testing for Cancer, Infectious Disease and Cardiovascular Disease MADISON, N.J., Feb. 24, 2011 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has signed a definitive agreement to acquire Athena...
Read More »Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference
MADISON, N.J., March 14 -- Quest Diagnostics Incorporated (NYSE:DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lehman Brothers Eleventh Annual Global Healthcare Conference on Wednesday, March 19, 2008, at The Loews Miami Beach Hotel, Miami, Florida. The Quest Diagnostics presentation is scheduled to begin at 9:00...
Read More »Quest Diagnostics Plans to Complete Acquisition of AmeriPath on May 31
LYNDHURST, N.J., May 30: Quest Diagnostics Incorporated (NYSE:DGX), the leading provider of diagnostic testing, information and services, announced today that it plans to complete its previously announced acquisition of AmeriPath, Inc. on May 31, 2007. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on May 29, 2007. About AmeriPath AmeriPath, a leading national...
Read More »Quest Diagnostics Completes Acquisition of AmeriPath
LYNDHURST, N.J., MAY 31: Quest Diagnostics Incorporated (NYSE:DGX), the leading provider of diagnostic testing, information and services, announced that today it completed its previously announced acquisition of AmeriPath, Inc., a national diagnostic testing company. This acquisition creates the world's premier cancer diagnostics company focused on dermatopathology, anatomic pathology and...
Read More »Quest Diagnostics Commences Cash Tender Offer for AmeriPath 10 1/2% Senior Subordinated Notes Due 2013
LYNDHURST, N.J., May 21: Quest Diagnostics Incorporated (NYSE:DGX), the nation's leading provider of diagnostics testing, information and services, announced today that it has commenced a cash tender offer for all of the outstanding $350,000,000 principal amount 10 1/2% Senior Subordinated Notes due 2013 (CUSIP Nos. 03071D AC 3 and 03071D AA 7) of AmeriPath, Inc. (AmeriPath). The tender offer is...
Read More »Quest Diagnostics to Acquire AmeriPath in a Transaction Valued at $2 Billion
o Establishes Leading Position in Cancer Diagnostics with a Focus on Dermatopathology, Anatomic Pathology and Molecular Diagnostics -- o Strengthens Leadership in Hospital and Esoteric Testing -- o Enhances Position as World's Premier Diagnostic Testing Company -- LYNDHURST, N.J. and PALM BEACH GARDENS, Fla., April 16 -- Quest Diagnostics Incorporated (NYSE:DGX), the leading provider of...
Read More »Quest Diagnostics Acquires HemoCue For Approximately US$420 Million, Entering Market for Near Patient Testing
LYNDHURST, New Jersey, February 1 -- Quest Diagnostics Incorporated (NYSE: DGX), the leading U.S. provider of diagnostic testing, information and services, announced today that it has acquired HemoCue, a Swedish company specializing in near patient testing, also known as point-of-care testing, from the private equity firm EQT II B.V. in a cash transaction valued at approximately US$420 million....
Read More »Quest Diagnostics to Speak at Wachovia Securities 2007 Healthcare Conference
LYNDHURST, N.J., Jan. 29 -- Quest Diagnostics Incorporated (NYSE:DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Wachovia Securities 2007 Healthcare Conference on Tuesday, January 30, 2007, at the Langham Hotel, Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 8:30 a.m. Eastern...
Read More »